Systemic lupus erythematosus diagnostics in the 'omics' era.
Systemic lupus erythematosus diagnostics in the 'omics' era.
复制标题
DOI：
10.2217/ijr.13.59
复制
发表时间：
2013-12-01
期刊：
影响因子：
--
通讯作者：
Mohan C
中科院分区：
文献类型：
--
作者：
Arriens C;Mohan C
系统性红斑狼疮是一种影响多个器官系统的复杂自身免疫性疾病。目前，诊断依赖于满足 ACR 概述的十一项标准中的至少四项。科学界积极寻求新诊断方法的发现，希望能够更好地识别疾病早期阶段的易感个体。在多个生物学层面进行了全面的研究，包括：DNA（或基因组学）、mRNA（或转录组学）、蛋白质（或蛋白质组学）和代谢物（或代谢组学）。 “组学”平台使我们能够以更高的分子分辨率重新检查系统性红斑狼疮。更重要的是，人们希望这些“组学”平台可以产生更新的系统性红斑狼疮生物标志物，帮助临床医生以更高的敏感性和特异性追踪疾病进程。
Systemic lupus erythematosus is a complex autoimmune disease affecting multiple organ systems. Currently, diagnosis relies upon meeting at least four out of eleven criteria outlined by the ACR. The scientific community actively pursues discovery of novel diagnostics in the hope of better identifying susceptible individuals in early stages of disease. Comprehensive studies have been conducted at multiple biological levels including: DNA (or genomics), mRNA (or transcriptomics), protein (or proteomics) and metabolites (or metabolomics). The ‘omics’ platforms allow us to re-examine systemic lupus erythematosus at a greater degree of molecular resolution. More importantly, one is hopeful that these ‘omics’ platforms may yield newer biomarkers for systemic lupus erythematosus that can help clinicians track the disease course with greater sensitivity and specificity.